Nanobiotix Receives Approval from ANSM to Start New Clinical Trial with NBTXR3

News   Jun 13, 2013

 
Nanobiotix Receives Approval from ANSM to Start New Clinical Trial with NBTXR3
 
 
 

RELATED ARTICLES

Cellular Valve Structure Opens Up Potential Novel Therapies

News

Biochemists have determined the detailed structure of a volume-regulated chloride channel. This cellular valve is activated in response to swelling to prevent the cell from bursting. The protein also plays an important role in the uptake of chemotherapeutics and the release of neurotransmitters after a stroke. The controlled regulation of its activity thus opens up a promising strategy for novel therapies.

READ MORE

Stem Cell Signaling Drives Mammary Gland Development

News

New research illuminates the biology of breast tissue development and may pave the way to new strategies for diagnosing or even treating cancer.

READ MORE

Abzena Selects Sartorius Stedim Biotech to Equip its US Based Development and Manufacturing Sites

News

Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has selected Sartorius Stedim Biotech as its preferred equipment supplier in the U.S.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Cancer Research

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE